<DOC>
	<DOCNO>NCT00005597</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness temozolomide treat patient unresectable metastatic gastrointestinal stromal tumor .</brief_summary>
	<brief_title>S9926 Temozolomide Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine complete partial response ( confirm unconfirmed ) patient unresectable metastatic gastrointestinal stromal tumor treat temozolomide . - Determine qualitative quantitative toxic effect regimen patient . OUTLINE : This multicenter study . Patients receive oral temozolomide daily day 1-5 . Treatment repeat every 4 week absence disease progression unacceptable toxicity . Patients achieve confirm complete response ( CR ) receive 2 additional course confirm CR . Patients follow every 3 month 1 year every 6 month 2 year . PROJECTED ACCRUAL : A total 20-40 patient accrue study within 13-27 month .</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm unresectable metastatic gastrointestinal stromal tumor ( GIST ) Primary ( gastrointestinal intraabdominal origin ) tumor At least 1 measurable lesion xray , CT , MRI , ultrasound , physical examination If lesion within prior radiation port use target lesion response assessment , lesion must demonstrate clear progression completion radiotherapy No uterine retroperitoneal sarcomas nonintraabdominal leiomyosarcoma PATIENT CHARACTERISTICS : Age : Not specify Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : WBC ( white blood count ) least 3,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) Renal : Creatinine great 1.5 time ULN Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No medical psychological condition would preclude study participation No major infection require systemic antibiotic No uncontrolled bacterial , viral , fungal infection No prior malignancy within past 5 year except : Adequately treat basal cell squamous cell skin cancer Adequately treat stage I II cancer complete remission Carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : At least 30 day since prior biologic therapy Prior imatinib mesylate adjuvant therapy metastatic disease allow Chemotherapy : No prior chemotherapy GIST At least 30 day since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No prior radiotherapy GIST No concurrent radiotherapy GIST Concurrent palliative radiotherapy painful metastasis ( encompass total portal great 5 x 5 cm ) allow Surgery : See Disease Characteristics At least 4 week since prior major surgery recover Other : At least 30 day since prior investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>gastrointestinal stromal tumor</keyword>
</DOC>